Core Insights - A significant breakthrough in cancer vaccine technology has been achieved by a research team led by Professor Chen Peng from Peking University, utilizing protein-targeted degradation techniques to transform cancer cells into active immune signals [1][2] - The new approach aims to address the issue of immune tolerance in cancer treatment, where a portion of patients do not respond to traditional immunotherapy due to cancer cells' ability to disguise themselves [1][2] Group 1 - The research team has developed a novel molecule called "intra-tumoral vaccine chimeras (iVAC)," which acts as a cancer cell identifier, disrupts immune "brakes," and delivers high-quality information to the immune system [2] - This new molecule can precisely infiltrate cancer cells, reprogramming them to become active immune messengers, thereby enhancing immune response [2] - The efficacy of the iVAC molecule has been validated through various experimental models, including cellular and mouse studies [2] Group 2 - The research team is actively working on the clinical translation of their findings, with plans to develop personalized cancer vaccines tailored to different patients in the future [2]

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [2][8]. Core Insights - The company is accelerating its overseas clinical trials for the drug SSGJ-707, with a significant upfront payment of 2.89 billion RMB from Pfizer, contributing to an expected total revenue of 9.63 billion RMB from this authorization in 2025 [6][7]. - Pfizer has initiated the first patient enrollment for the Phase III clinical trial of SSGJ-707 targeting mCRC, marking a significant milestone as the first MRCT Phase III trial conducted by a multinational corporation in the PD-1/VEGF field [7]. - The company has a rich pipeline with multiple catalysts expected in 2026, including the anticipated approval of three new molecular entities and the ongoing progress of global Phase III clinical trials for SSGJ-707 [7]. Financial Projections - Revenue projections for the company are estimated at 19.216 billion RMB for 2025, with a growth rate of 111%, followed by 11.085 billion RMB in 2026, reflecting a decline of 42%, and a recovery to 12.906 billion RMB in 2027, with a growth rate of 16% [9][10]. - The net profit attributable to the parent company is projected to be 10.967 billion RMB in 2025, with a significant increase of 425%, followed by a decrease to 2.443 billion RMB in 2026, and an increase to 3.411 billion RMB in 2027 [9][10]. - The report anticipates a price-to-earnings (P/E) ratio of 4.8x for 2025, 21.6x for 2026, and 15.4x for 2027, indicating a potential for valuation adjustments as new products are launched [9][10].

Core Viewpoint - The company, Valiant Bio-B (09887), has seen its stock price increase by over 8%, currently trading at 64.75 HKD, with a transaction volume of 44.92 million HKD, following the announcement of its dual-specific antibody LBL-034 receiving Fast Track designation from the FDA for treating relapsed/refractory multiple myeloma [1]. Group 1 - Valiant Bio-B's LBL-034 is developed based on the TCE technology platform LeadsBody, featuring a unique 2:1 structure and conditional activation [1]. - The company has a comprehensive layout for next-generation tumor immunotherapy, utilizing its agonist platform, TCE platform, and ADC [1]. - Since 2015, the company has focused on "technology platform + innovative targets," covering cutting-edge areas such as immune checkpoints and multi-specific antibodies, thereby building a differentiated pipeline [1].

Core Insights - The company is strategically positioned in the next-generation tumor immunotherapy space through its platforms, including the Agonist platform, TCE platform, and ADC, focusing on innovative targets and differentiated pipelines [1] Group 1: Product Development - LBL-024 (PDL1/4-1BB bispecific antibody) has shown historical best data in lung neuroendocrine carcinoma, with excellent efficacy in first-line SCLC and promising preliminary results in NSCLC; it demonstrates a low incidence of ≥3 grade liver enzyme elevation at only 1.3%, indicating superior safety [2] - LBL-034 (GPRC5D/CD3 bispecific antibody) has a 2:1 structure that enhances TAA binding while balancing efficacy and safety; in I/II clinical studies, it achieved an ORR of 77.8% at 400μg/kg and 90.9% at 800μg/kg, comparable to CAR-T efficacy [3] Group 2: Clinical Research and Pipeline - LBL-024 is the first 4-1BB targeted molecule to reach critical clinical stages globally, with ongoing clinical research approved in multiple cancer types including SCLC, BTC, OC, and others, showing promising clinical effects [2] - Other pipeline developments include BDCA2×TACI expected to file IND in the second half of 2025, a CD19/BCMA/CD3 trispecific antibody IND anticipated in Q1 2026, and DLL3 TCE ADC expected to file IND in the first half of 2027 [3] Group 3: Financial Projections - Revenue forecasts for the company are projected at 1.80 billion, 0.94 billion, and 0.10 billion yuan for 2025, 2026, and 2027 respectively, with growth rates of 833%, -48%, and -90% [3] - Using a DCF model with a WACC of 8.78% and a perpetual growth rate of 1%, the company's fair stock price is estimated at 101.86 HKD, leading to a fair market capitalization of 20.3 billion HKD [3]

Summary of Key Points from the Conference Call Industry Overview - The conference focused on the pharmaceutical industry, particularly the advancements in drug development and the impact of AI technology on research and development processes across major multinational corporations (MNCs) [1][3][6]. Core Insights and Arguments 1. **AI in Drug Development**: Major pharmaceutical companies like JSK, AstraZeneca, BMS, Pfizer, Eli Lilly, and Novartis are leveraging AI to enhance R&D efficiency and reduce costs. For instance, JSK has made significant progress in molecular prediction design and disease modeling using AI [1][3]. 2. **Impact of U.S. Policies**: Policies from the Trump administration, such as the Inflation Reduction Act (IRI) and Most Favored Nation (MFN) treatment, have had a limited impact on global sales for pharmaceutical companies. Many firms are confident that increasing innovation funding can offset price declines in the U.S. market [1][7]. 3. **Weight Management Products**: Companies like Novo Nordisk and Eli Lilly are facing pricing challenges with their weight management products, which are limiting patient access. However, they believe that over time, more patients will be able to afford these treatments, thus expanding market share [1][7]. 4. **Cancer Research Initiatives**: Pfizer plans to initiate multiple analysis studies targeting various cancers and is focusing on the ADC field related to integrin V6. Collaborations are also noted, such as AbbVie with Rongchang Biotech and BMS with OncoOne [1][9]. 5. **Investment in Cardiovascular and Metabolic Areas**: AstraZeneca is investing heavily in cardiovascular, renal, and metabolic research, including the introduction of oral GLP-1 small molecules [1][10][11]. Additional Important Insights - **Chinese Pharmaceutical Companies**: Chinese firms are increasingly recognized for their innovation capabilities and are becoming integral to the strategies of major overseas pharmaceutical companies. The Chinese CRO industry is also gaining importance due to its scale and cost advantages [4][15][17]. - **Future Goals of AstraZeneca**: AstraZeneca aims to achieve $80 billion in revenue by 2030, with significant investments in cardiovascular and oncology sectors [11]. - **Pfizer's Market Strategy**: Pfizer is focusing on the weight management market and plans to disclose data on GLP-1 monthly dosing regimens, with expectations of the global weight management market reaching $150 billion by 2030 [12]. - **Clinical Research Developments**: Companies like Rongchang Biotech and DiZhe Pharma are advancing their clinical research, with multiple trials planned for new drug candidates [21][22]. This summary encapsulates the key points discussed during the conference, highlighting the ongoing trends and strategic directions within the pharmaceutical industry.

Core Viewpoint - Tumor immunotherapy, particularly immune checkpoint blockade (ICB) targeting the PD-1/PD-L1 pathway, shows promise in treating advanced cancers but is limited by insufficient response rates. Recent findings suggest that Gasdermin D-mediated pyroptosis can trigger a robust systemic immune response, with only 15% of pyroptotic tumor cells capable of eliminating the entire tumor, presenting a new strategy for enhancing anti-tumor immunity [2][3][10]. Summary by Sections Research Development - A new self-luminous photodynamic therapy system, CC@PDC, has been developed to efficiently activate pyroptosis and stimulate anti-tumor immunity. This system, when used in conjunction with anti-PD-L1 antibodies, demonstrates superior anti-tumor and immune effects, offering a novel strategy for cancer treatment [3][10]. Mechanism and Composition - The CC@PDC system is designed with efficient resonance energy transfer, effective generation of singlet oxygen (1 O₂), and strong pyroptosis induction capabilities. It consists of amphiphilic porphyrin lipids, camptothecin derivatives, and a targeted assembly that encapsulates oleic acid-modified calcium peroxide and a specific compound to enhance its efficacy in acidic tumor microenvironments [7][10]. Key Findings - The study highlights that the camptothecin-enhanced self-luminous photodynamic chemotherapy can synergistically induce tumor cell pyroptosis and, when combined with anti-PD-L1 antibodies, significantly enhances the anti-tumor immune response, providing a promising new approach for cancer therapy [10][11].

Core Viewpoint - Hanse Aitai Biopharmaceutical Technology (Wuhan) Co., Ltd. successfully listed on the Hong Kong Stock Exchange, marking it as the second company from Wuhan to go public under the HKEX's 18A biotech rules. The company focuses on developing innovative drugs for cancer and autoimmune diseases, addressing unmet medical needs in these areas [3][4]. Group 1: IPO Details - Hanse Aitai issued 18.321 million H-shares at an offering price of HKD 32 per share, raising a total of HKD 586 million, with a market capitalization of nearly HKD 4.4 billion at issuance [3]. - On its first trading day, the opening price was HKD 28.9, and the latest market capitalization was HKD 3 billion [3]. - The company has completed three rounds of financing prior to the IPO, totaling approximately RMB 154 million, with major investors including Betta Pharmaceuticals and Longpan Investment [4]. Group 2: Product Pipeline and R&D Focus - The core product, HX009, is the world's only PD-1/SIRPα dual-function antibody fusion protein, currently in Phase II clinical trials in China after completing Phase I trials in China and Australia [4][20]. - Another innovative product, HX044, has initiated Phase I clinical trials for advanced solid tumors in both China and Australia [4][21]. - The company plans to allocate approximately 35% of the raised funds to advance HX009, 33% to develop HX301 and HX044, and 5% for commercialization preparations [4]. Group 3: Founder's Background and Company Development - Founder Zhang Faming, who has a strong academic and professional background in biochemistry and pharmaceutical development, has previously founded and sold successful biotech companies [10][11]. - Hanse Aitai was established in 2014 and has since focused on developing next-generation immunotherapies, particularly targeting the limitations of existing PD-1 therapies [15][17]. - The company has built a robust R&D team, integrating expertise from various fields to enhance its drug development capabilities [15][20]. Group 4: Market Context and Competitive Landscape - The global PD-1/PD-L1 antibody market is projected to reach USD 53.7 billion by 2024, with expectations to grow to USD 72.5 billion by 2030, highlighting the competitive nature of the immunotherapy sector [25]. - Hanse Aitai's dual-target design for HX044 aims to address the challenges of PD-1 resistance, positioning the company in a competitive landscape with several other firms pursuing similar therapeutic strategies [26][28]. - The company is one of the few globally to have two clinical-stage products targeting the SIRPα pathway, indicating significant long-term collaboration potential [28].

Company Overview - Junshi Biosciences Co., Ltd. (君赛生物) has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities acting as the sole sponsor [1] - The company focuses on innovative cell therapies and drug development for solid tumors, aiming to provide safer, more effective, and affordable immunotherapy options [3][4] Product Information - The core product, GC101, is the world's first tumor-infiltrating lymphocyte (TIL) therapy that does not require high-intensity lymphodepletion or IL-2 administration, potentially becoming the first TIL therapy approved in China [3][4] - Clinical trials have shown that GC101 can provide objective response rates of 30% for metastatic melanoma and 41.7% for non-small cell lung cancer, with a median progression-free survival of 5.5 months for melanoma patients [4] Financial Performance - The company reported revenues of RMB 6.812 million, RMB 3.372 million, and RMB 6.830 million for the fiscal years ending June 30, 2023, 2024, and 2025, respectively [5] - Losses for the same periods were RMB 94.391 million, RMB 163.652 million, and RMB 97.580 million, indicating significant financial challenges [6][7] Market Overview - The global oncology drug market is projected to grow to USD 253.3 billion by 2024, with a compound annual growth rate (CAGR) of 13.9% from 2020 to 2024 [8] - The Chinese oncology drug market is expected to reach RMB 258.2 billion by 2024, with a CAGR of 6.9% during the same period [11] TIL Therapy Market - The global TIL therapy market is anticipated to grow from USD 10.4 million in 2024 to USD 1.692 billion by 2030, with a CAGR of 59.3% from 2024 to 2028 [14] - In China, the TIL therapy market is expected to reach USD 200 million by 2030, with a CAGR of 40.0% from 2030 to 2035, outpacing global growth rates [14][17] Board of Directors - The board consists of 9 members, including 4 executive directors, 2 non-executive directors, and 3 independent non-executive directors, with a term of 3 years [18] Shareholding Structure - As of December 5, 2025, Dr. Jin holds a 34.5% stake in the company, with other significant shareholders including Kai Tai Capital and Yuan He Yuan Dian [21][23]

Core Viewpoint - Junsei Biotech has submitted its listing application to the Hong Kong Stock Exchange, with CITIC Securities as its sole sponsor [1] Company Overview - Junsei Biotech focuses on innovative cell therapies and drug development for solid tumors, aiming to create safer, more effective, and affordable immunotherapy options [3] - The company's core product, GC101, is the world's first tumor-infiltrating lymphocyte (TIL) therapy that does not require high-intensity lymphodepletion or IL-2 administration, potentially becoming the first TIL therapy approved in China [3][4] - GC101 has shown objective response rates of 30% in advanced melanoma and 41.7% in advanced non-small cell lung cancer patients who failed standard treatments [4] Financial Performance - Revenue for the fiscal years ending June 30, 2023, 2024, and 2025 was recorded at RMB 6.812 million, RMB 3.372 million, and RMB 6.830 million, respectively [5] - The company reported losses of RMB 94.391 million, RMB 163.652 million, and RMB 97.580 million for the same periods [6][7] Industry Overview - The global oncology drug market is projected to grow to USD 253.3 billion by 2024, with a compound annual growth rate (CAGR) of 13.9% from 2020 to 2024 [8] - The Chinese oncology drug market is expected to reach RMB 258.2 billion in 2024, with a CAGR of 6.9% from 2020 to 2024 [11] - The TIL therapy market is anticipated to grow significantly, reaching USD 1.04 billion in 2024 and USD 16.92 billion by 2030, with a CAGR of 59.3% from 2024 to 2028 [14][17] Clinical and Regulatory Landscape - The TIL therapy market is expected to expand rapidly due to clinical, technical, regulatory, and funding support, with promising results in various solid tumors [17] - GC101 is currently undergoing critical Phase II clinical trials for melanoma and is in Phase I for non-small cell lung cancer, with plans to submit a Biologics License Application (BLA) by 2026 [4]

Investment Rating - The report assigns an "Accumulate" rating for the company, marking its first coverage [1]. Core Insights - The company positions itself as a leader in next-generation tumor immunotherapy, leveraging three major technology platforms to establish a high-quality R&D pipeline [3][12]. - The 4-1BB co-stimulation signal market shows significant potential, with the product LBL-024 demonstrating notable competitive advantages [4][25]. - The TCE technology platform has been validated through clinical data, with LBL-034 showing superior efficacy and safety compared to competitors [5][22]. - The company is currently in the new drug development investment phase, with projected revenues of 175 million, 314 million, and 187 million yuan for 2025, 2026, and 2027 respectively, and expected net losses of 200 million, 99 million, and 262 million yuan [5]. Summary by Sections Section 1: Three Platforms Supporting Next-Generation Tumor Immunotherapy - The company aims to address diseases that current therapies, such as PD-1/PD-L1 antibodies, cannot treat, focusing on cutting-edge targets like 4-1BB and PD-L1 dual targets [3][12]. - The R&D team is robust, with extensive experience in new drug development, and has established a pipeline of 14 new drugs, including 6 in clinical stages and 4 with leading global clinical progress [13][22]. Section 2: 4-1BB Co-Stimulation Signal Market Potential - 4-1BB serves as a co-stimulation immune checkpoint molecule, providing a second signal for T-cell activation [25][31]. - LBL-024, a low-affinity 4-1BB dual antibody, has shown excellent efficacy and safety balance in clinical trials, with significant improvements in overall survival compared to existing treatments [4][35]. Section 3: TCE Technology Platform Validation - The TCE platform, particularly the CD3 TCE drug LBL-034, has demonstrated the ability to conditionally activate T-cells in tumor microenvironments, showing advantages in safety and efficacy over similar products [5][22]. - The company has plans for new generation TCE and TCE ADC platforms, with the CD3/MUC16 TCE positioned among the top globally [5][22].